Going into 2025, we expect pharma brands and their advertising partners to use past learnings – and, more importantly – ...

Changing a cultural undertow is one of the hardest leadership challenges in any industry, and perhaps even more so in the ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan in advanced non-small cell lung cancer, ABBV-706 in high-grade neuroendocrine ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...